Natera director Sheena’s trusts dispose of $7.0m in NTRA stock

On September 23, 2026, trusts managed by Natera director Jonathan Sheena disposed of $7,008,972 worth of NTRA stock. The shares were sold at prices between $385.1025 and $390.525 each. Since the sale, the stock price has risen to $412.56, which is 1% below its 52-week high of $415.75, marking a 153% increase over the past year. The transactions involved shares indirectly held by the Caraluna 1 Trust and Caraluna 2 Trust.

Sheena explicitly states that he does not have a beneficial interest in these securities, which are held for the benefit of the trusts' beneficiaries. All of the sales were executed under a pre-approved Rule 10b5-1 trading plan, which Sheena established on June 11, 2026. According to InvestingPro analysis, NTRA stock appears to be overvalued relative to its Fair Value.

NTRA is currently trading near its 52-week high, with noticeable price volatility, as noted by two of InvestingPro's 18 exclusive tips. Recently, Natera posted strong financial results for Q2 2026, with revenue at approximately $753 million, exceeding analysts' expectations of $661.26 million. The company cited accelerated growth in its primary businesses, along with raising its full-year revenue guidance.

Natera also raised its total addressable market for its minimal residual disease (MRD) testing in the latest financial report. Furthermore, Rothschild Redburn initiated coverage on Natera with a Buy rating and a price target of $385, based on the company's leadership in MRD testing, highlighted by its Signatera tumor-informed test.

Natera is also known for its Latitude test in colorectal cancer and its development of a multi-cancer early detection screening test.